Figures
Tables
Supplementary material
Files in this Data Supplement:
- Supplementary material -
Internal validation of CCL18 cut-off for identifying SSc patients
who are going to have subsequent lung disease worsening or to die within 2 years
Cross sectional analysis of the population at baseline - Figure S1 - Serum CCL18 levels from systemic sclerosis patients with and without interstitial lung disease at baseline and healthy controls. Systemic sclerosis patients with interstitial lung disease at baseline ( ), systemic sclerosis patients without interstitial lung disease at baseline ( ) and healthy controls ( ).
- Supplementary material -
Internal validation of CCL18 cut-off for identifying SSc patients
who are going to have subsequent lung disease worsening or to die within 2 years